Literature DB >> 22491335

Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review.

Rishi Desai1, Christal D Hembree, Andreas Handel, Jonathan E Matthews, Benjamin W Dickey, Sharla McDonald, Aron J Hall, Umesh D Parashar, Juan S Leon, Benjamin Lopman.   

Abstract

BACKGROUND: Noroviruses (NoVs) are the most common cause of epidemic gastroenteritis; however, the relative impacts of individual factors underlying severe illness are poorly understood. This report reviews published NoV outbreak reports to quantify hospitalization and mortality rates and assess their relationship with outbreak setting, transmission route, and strain.
METHODS: Using a string of terms related to "norovirus" and "outbreak," we 2435 nonduplicate articles identified in PubMed, EMBASE, and Web of Knowledge published between January 1993 and June 2011. Inclusion criteria included outbreaks with a minimum of 2 ill persons with a common exposure and at least 1 reverse-transcription polymerase chain reaction-confirmed case of NoV disease. Univariate analyses were performed, and multivariable models were fitted to estimate the independent effect of each factor.
RESULTS: We analyzed 843 NoV outbreaks reported in 233 published articles from 45 countries. Based upon 71724 illnesses, 501 hospitalizations, and 45 deaths, overall hospitalization and mortality rates were 0.54% and 0.06%, respectively. In multivariate analysis, genogroup 2 genotype 4 (GII.4) NoV strains were associated with higher hospitalization (incidence rate ratio [IRR], 9.4; 95% confidence interval [CI], 6.1-14.4; P< .001) and mortality rates (IRR, 3.1; 95% CI, 1.3-7.6; P = .01). Deaths were much more likely to occur in outbreaks occurring in healthcare facilities (IRR, 60; 95% CI, 6-109; P = .01).
CONCLUSIONS: Our review suggests that hospitalizations and deaths were more likely in outbreaks associated with GII.4 viruses, independent of other factors, and underscores the importance of developing vaccines against GII.4 viruses to prevent severe disease outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 22491335      PMCID: PMC3491774          DOI: 10.1093/cid/cis372

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  21 in total

1.  Methodological problems in investigating disease clusters.

Authors:  D Wartenberg; M Greenberg
Journal:  Sci Total Environ       Date:  1992-12-15       Impact factor: 7.963

2.  Emergence of a new norovirus genotype II.4 variant associated with global outbreaks of gastroenteritis.

Authors:  Rowena A Bull; Elise T V Tu; Christopher J McIver; William D Rawlinson; Peter A White
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

3.  Risk factors for symptomatic and asymptomatic norovirus infection in the community.

Authors:  G Phillips; C C Tam; L C Rodrigues; B Lopman
Journal:  Epidemiol Infect       Date:  2010-12-17       Impact factor: 2.451

4.  Norovirus vaccine against experimental human Norwalk Virus illness.

Authors:  Robert L Atmar; David I Bernstein; Clayton D Harro; Mohamed S Al-Ibrahim; Wilbur H Chen; Jennifer Ferreira; Mary K Estes; David Y Graham; Antone R Opekun; Charles Richardson; Paul M Mendelman
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

5.  Multiplex real time RT-PCR for the detection and quantitation of norovirus genogroups I and II in patients with acute gastroenteritis.

Authors:  Xiaoli L Pang; Jutta K Preiksaitis; Bonita Lee
Journal:  J Clin Virol       Date:  2005-06       Impact factor: 3.168

6.  The frequency of a Norwalk-like pattern of illness in outbreaks of acute gastroenteritis.

Authors:  J E Kaplan; R Feldman; D S Campbell; C Lookabaugh; G W Gary
Journal:  Am J Public Health       Date:  1982-12       Impact factor: 9.308

7.  Epidemics of gastroenteritis during 2006 were associated with the spread of norovirus GII.4 variants 2006a and 2006b.

Authors:  Elise T-V Tu; Rowena A Bull; Gail E Greening; Joanne Hewitt; Michael J Lyon; John A Marshall; Christopher J McIver; William D Rawlinson; Peter A White
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

8.  Clinical manifestation of norovirus gastroenteritis in health care settings.

Authors:  Ben A Lopman; Mark H Reacher; Ian B Vipond; Joyshri Sarangi; David W G Brown
Journal:  Clin Infect Dis       Date:  2004-07-09       Impact factor: 9.079

9.  Fecal viral load and norovirus-associated gastroenteritis.

Authors:  Martin C W Chan; Joseph J Y Sung; Rebecca K Y Lam; Paul K S Chan; Nelson L S Lee; Raymond W M Lai; Wai K Leung
Journal:  Emerg Infect Dis       Date:  2006-08       Impact factor: 6.883

10.  Two epidemiologic patterns of norovirus outbreaks: surveillance in England and wales, 1992-2000.

Authors:  Benjamin A Lopman; Goutam K Adak; Mark H Reacher; David W G Brown
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more
  74 in total

Review 1.  Burden of norovirus in healthcare facilities and strategies for outbreak control.

Authors:  A Kambhampati; M Koopmans; B A Lopman
Journal:  J Hosp Infect       Date:  2015-02-04       Impact factor: 3.926

2.  New strains of norovirus and the mystery of viral gastroenteritis epidemics.

Authors:  Bonita E Lee; Xiao-Li Pang
Journal:  CMAJ       Date:  2013-09-03       Impact factor: 8.262

Review 3.  Norovirus Illnesses in Children and Adolescents.

Authors:  Minesh P Shah; Aron J Hall
Journal:  Infect Dis Clin North Am       Date:  2018-03       Impact factor: 5.982

Review 4.  Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis.

Authors:  Sharia M Ahmed; Aron J Hall; Anne E Robinson; Linda Verhoef; Prasanna Premkumar; Umesh D Parashar; Marion Koopmans; Benjamin A Lopman
Journal:  Lancet Infect Dis       Date:  2014-06-26       Impact factor: 25.071

Review 5.  Advances in laboratory methods for detection and typing of norovirus.

Authors:  Jan Vinjé
Journal:  J Clin Microbiol       Date:  2014-07-02       Impact factor: 5.948

6.  Serological Correlates of Protection against a GII.4 Norovirus.

Authors:  Robert L Atmar; David I Bernstein; G Marshall Lyon; John J Treanor; Mohamed S Al-Ibrahim; David Y Graham; Jan Vinjé; Xi Jiang; Nicole Gregoricus; Robert W Frenck; Christine L Moe; Wilbur H Chen; Jennifer Ferreira; Jill Barrett; Antone R Opekun; Mary K Estes; Astrid Borkowski; Frank Baehner; Robert Goodwin; Anthony Edmonds; Paul M Mendelman
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

Review 7.  Norovirus.

Authors:  Elizabeth Robilotti; Stan Deresinski; Benjamin A Pinsky
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

8.  Immune-Focusing Properties of Virus-like Particles Improve Protective IgA Responses.

Authors:  Taishi Onodera; Kana Hashi; Rajni Kant Shukla; Motohiro Miki; Reiko Takai-Todaka; Akira Fujimoto; Masayuki Kuraoka; Tatsuya Miyoshi; Kazuo Kobayashi; Hideki Hasegawa; Manabu Ato; Garnett Kelsoe; Kazuhiko Katayama; Yoshimasa Takahashi
Journal:  J Immunol       Date:  2019-11-08       Impact factor: 5.422

Review 9.  Infection control for norovirus.

Authors:  L Barclay; G W Park; E Vega; A Hall; U Parashar; J Vinjé; B Lopman
Journal:  Clin Microbiol Infect       Date:  2014-07-16       Impact factor: 8.067

Review 10.  Epidemiology of human noroviruses and updates on vaccine development.

Authors:  Sasirekha Ramani; Robert L Atmar; Mary K Estes
Journal:  Curr Opin Gastroenterol       Date:  2014-01       Impact factor: 3.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.